Purple Biotech Ltd. Sponsored ADR PPBT

1.49 0.01 0.68% as of 25 Sep

Follow PPBT

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio	+8 more quarters Free account	—	—	—	—
EV/Sales		—	—	—	—
EV/FCF		—	—	—	—
Quick Ratio		1.73	1.23	1.40	3.42
Current Ratio		1.78	1.27	1.48	3.70
Net Debt/EBITDA		7.99	0.41	2.94	4.97
Debt/Assets		0.00%	0.00%	0.00%	0.00%
Debt/Equity		0.00	0.00	0.00	0.00
Asset Turnover		0.00	0.00	0.00	0.00
Operating CF/Net income		0.82	0.05	36.29	(5.68)
Capex/Depreciation		0.14	(0.17)	0.00	(0.04)
Interest Coverage		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue		0.00%	0.00%	0.00%	0.00%
Intangible Assets out of Total Assets		0.71	0.42	0.51	0.52
Share Based Compensation of Revenue		0.00%	0.00%	0.00%	0.00%
Free Cash Flow Yield		—	—	—	—
Revenue per Share		0.00	0.00	0.00	0.00
Operating CF per Share		(2.34)	(2.22)	(3.35)	(2.30)
Capex per Share		0.02	(0.02)	0.00	0.00
Free Cash Flow per Share		(2.32)	(2.24)	(3.35)	(2.31)
Cash per Share		22.95	19.94	6.90	5.62
Shareholders Equity per Share		72.04	20.12	10.38	11.25
Interest Debt per Share		0.00	0.00	0.00	0.00
Book value per Share		72.04	20.12	10.38	11.25
Free Cash Flow		(1.06)	(1.08)	(3.12)	(2.51)
Working Capital		4.72	2.11	2.19	4.81
Capital Expenditures		0.01	(0.01)	—	0.00
Net Current Asset Value		4.53	1.95	2.03	4.64
EV/EBIT		—	—	—	—
Capex to Sales		0.00	0.00	—	0.00
Net Profit Margin		0.00%	0.00%	0.00%	0.00%
Other line items
Average Payables		1.26	1.76	0.86	0.58
Average Assets		37.08	27.31	25.01	24.27
Average Common Equity		31.14	21.29	21.18	22.13

Columns are period end dates

Powerpack